November 9, 2007
Takeda Pharmaceutical Company Limited
Osaka, Japan, November 9, 2007 --- During the American Heart Association’s Scientific Session 2007, held at Orland, Miami, the results of the HIJ-CREATE[*] study (“CREATE study”) were presented in late-breaking clinical trials session.
[*] HIJ-CREATE: The Heart Institute of Japan-Candesartan Randomized trial for Evaluation in Coronary Artery Disease.
This is a large-scaled outcome study with coronary artery disease patients with hypertension in Japan, comparing the reduction of incidence of major adverse cardiovascular events (“MACE”) between therapy with candesartan cilexetil (tradename in Japan: Blopress®), an angiotensin receptor blocker (“ARB”), and that with non-ARB standard therapy, and the total number of patients is 2,049. The CREATE study is an Investigators Initiated Trial (“IIT”) started in June 2001, by 14 medical institutions headed by Department of Cardiology, Graduate School of Medicine, Tokyo Women’s Medical University.